Harris Interactive

Data Backs Gender-specific Dosing of Insomnia Drug

A report presented at a recent American Psychiatric Assn. meeting supports gender-specific dozing of Intermezzo sublingual sleep-aid tablets.

The new prescription sleep aid Intermezzo (zolpidem tartrate) sublingual tablet CIV is the first and only prescription sleep aid approved by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep, and the patient has at least four hours of bedtime remaining before the planned time of waking.

Your rating: None Average: 5 (1 vote)
Syndicate content